PLEXOVAL I study disrupted by the Covid-19 response
- PLEXOVAL is a world-first study using a cellfree, platelet-derived exosome product, manufactured using Exopharm's proprietary LEAP Technology, for wound healing
- COVID-19 has impacted the progress of Exopharm’s PLEXOVALI human trial, and will likely reduce recruitment numbers, neither Cohorts 1 and 2 will fully recruit, and the study report will be delayed
- Initial results from Cohort2 may be available in the coming months
- Planning is underway, for the follow-on study, using allogeneic(off-the-shelf) Plexaris
http://exopharm.com/wp-content/uploads/2020/04/72._20.04.01-Plexoval-update-Exopharm-Ltd-ASX_EX1.pdf
- Forums
- ASX - By Stock
- TYP
- Buy Recommendation
Buy Recommendation, page-68
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TYP (ASX) to my watchlist
|
|||||
Last
2.1¢ |
Change
-0.001(4.55%) |
Mkt cap ! $22.87M |
Open | High | Low | Value | Volume |
2.2¢ | 2.2¢ | 2.1¢ | $4.354K | 203.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
9 | 1202944 | 2.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.1¢ | 104 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 18750 | 0.024 |
1 | 25000 | 0.021 |
9 | 1202944 | 0.020 |
8 | 1307398 | 0.019 |
6 | 832509 | 0.018 |
Price($) | Vol. | No. |
---|---|---|
0.021 | 500104 | 2 |
0.022 | 930652 | 3 |
0.023 | 403477 | 3 |
0.024 | 40529 | 1 |
0.025 | 721144 | 4 |
Last trade - 10.15am 03/09/2024 (20 minute delay) ? |
Featured News
TYP (ASX) Chart |